Fluconazole
- PMID: 30725843
- Bookshelf ID: NBK537158
Fluconazole
Excerpt
Fluconazole is a member of the triazole family and stands as a cornerstone in the realm of antifungal agents, offering widespread therapeutic utility. This medication addresses a spectrum of fungal afflictions, including vaginal candidiasis, oropharyngeal and esophageal candidiasis, urinary tract infections, peritonitis, and systemic Candida infections. Its efficacy extends to candidemia, disseminated candidiasis, pneumonia, and cryptococcal meningitis. Beyond treatment of active disease, fluconazole serves a crucial prophylactic role, reducing the incidence of candidiasis in patients undergoing bone marrow transplantation subjected to cytotoxic chemotherapy or radiation therapy. This activity details the drug's indications, mechanism of action, optimal dosing, noteworthy adverse effects, contraindications, monitoring parameters, and potential toxicity. Equipping healthcare providers with this understanding empowers them to navigate patient therapy effectively, fostering optimal outcomes in the battle against fungal infections.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, Johnson RH, Kusne S, Lisse J, MacDonald JD, Meyerson SL, Raksin PB, Siever J, Stevens DA, Sunenshine R, Theodore N. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clin Infect Dis. 2016 Sep 15;63(6):e112-46. - PubMed
-
- Amichai B, Grunwald MH. Adverse drug reactions of the new oral antifungal agents--terbinafine, fluconazole, and itraconazole. Int J Dermatol. 1998 Jun;37(6):410-5. - PubMed
Publication types
LinkOut - more resources
Full Text Sources